Capricor Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-105.0M | $-40.5M | $-22.3M | $-29.0M | $-20.0M | $-13.7M | $-7.6M | $-15.2M |
| Depreciation & Amortization | $1.9M | $1.4M | $1.1M | $533.1K | $245.7K | $143.9K | $172.0K | $157.7K |
| Depreciation | $1.9M | $1.4M | $1.1M | $533.1K | $243.5K | $139.6K | $128.7K | $114.4K |
| Amortization | — | — | — | $0 | $2.2K | $4.3K | $43.3K | $43.3K |
| Stock-Based Compensation | — | $9.8M | $7.4M | $4.5M | $3.0M | $2.0M | $701.0K | $1.7M |
| Net Cash from Operating Activities | $-69.8M | $-40.0M | $-25.6M | $4.9M | $-16.8M | $-10.1M | $-6.8M | $-13.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $2.9M | $1.2M | $1.3M | $2.0M | $1.2M | $547.6K | $0 | $316.5K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $97.5M | $-116.2M | $5.1M | $-35.1M | $-1.2M | $5.4M | $-3.0M | $4.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | $0 | $193 | $0 |
| Net Cash from Financing Activities | $248.9M | $152.8M | $25.6M | $4.9M | $20.2M | $33.4M | $9.2M | $6.9M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-72.7M | $-41.2M | $-26.9M | $2.9M | $-18.0M | $-10.6M | $-6.8M | $-14.2M |